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Background. In Haiti, breast cancer patients present at such advanced stages that even modern therapies offer modest survival
benefit.Identifyingthepersonal,sociocultural,andeconomicbarriers-to-caredelayingpatientpresentationiscrucialtocontrolling
disease. Methods. Patients presenting to the Hˆ opital Bon Sauveur in Cange were prospectively accrued. Delay was defined as 12
weeks or longer from initial sign/symptom discovery to presentation, as durations greater than this cutoff correlate with reduced
survival.A matched case-control analysis withmultivariate logisticregressionwas usedtoidentifyfactorspredictingdelay.Results.
Of 𝑁 = 123 patients accrued, 90 (73%) reported symptom-presentation duration and formed the basis of this study: 52 patients
presented within 12 weeks of symptoms, while 38 patients waited longer than 12 weeks. On logistic regression, lower education
status (OR = 5.6, 𝑃 = 0.03), failure to initially recognize mass as important (OR = 13.0, 𝑃 < 0.01), and fear of treatment cost (OR
= 8.3, 𝑃 = 0.03) were shown to independently predict delayed patient presentation. Conclusion. To reduce stage at presentation,
futureinterventionsmusteducatepatientsontherecognitionofinitialbreastcancersignsandsymptomsandaddresscostconcerns
by providing care free of charge and/or advertising that existing care is already free.
1. Introduction
Breast cancer remains the most common cancer and most
common cause of cancer-related death amongt women
worldwide [1]. While incidence rates have historically been
higher in the developed world, recent evidence suggests an
alarming increase in both incidence and mortality in low-
income developing countries (LIDCs) [2]. Coupled with
stable-to-decliningage-standardizedmortalityratesindevel-
oped countries [3], an increasing number of preventable
breast cancer deaths will continue to shift to LIDCs world-
wide.
Within LIDCs, the problem is further exacerbated as
relative survival rates (approximated as the complement of
the mortality-to-incidence ratio [4] )a r el o w e rd u et ob o t h
advanced stage at presentation and inaccessibility of poten-
tially curative therapy [2, 5]. For example, in one study of
sub-Saharan Africa, 90% of breast cancer patients presented
withstageIIIorIVdisease,amediantumorsizeof10cm,and
palpable nodal metastasis [6]. These patterns of disease can
be so advanced that even optimal western therapy may offer
minimal survival benefit. This is distinctly different than in
t h ed e v e l o p e dw o r l d ,w h e r et h em a j o r i t yo fw o m e np r e s e n t
with early-stage disease, and more than 80% survive at least
for5years[7].Furthermore,theseadvancedstagesarechiefly
the result of delayed presentation [8]. Delays to seek for
care longer than 12 weeks have been shown in a systematic
reviewinvolving87studiestocorrelatewithdecreased5-year2 Journal of Oncology
Table 1: Potential risk factors for delayed patient presentation (barriers-to-care).
Personal Sociocultural Economic
Age
Ethnicity
Marital status
Clinical presentation
Personal history
Family history
Breast cancer awareness
Failure to initially recognize mass as important
Lack of breast-self exam (BSE) use
Alternative therapy use
Fear of examination
Fear of treatment
Stigma of disease
Denial/anxiety
Fear of cost of travel
Fear of cost of treatment
Obligations at home/work
Access to health systems
Income status
Education status
Note: variables in bold were shown to predict patient delay in the multivariate logistic regression analysis (see Figure 2).
s u rv i v a l ,t h o u g hi ti sl i k e l yt h a td e l a yi sac o n t i n u o u sv a r i a b l e
in regard to outcome [9]. Hence, to maximize benefit, future
interventions to control breast cancer within LIDCs must
address delayed presentation in addition to extending access
to modernized care.
Delayed patient presentation refers to a prolonged inter-
val between discovery of initial sign/symptom and presen-
tation to a qualified medical provider. A recent systematic
reviewbyourgroupexaminingcausesofpatientdelaywithin
LIDCsgroupedthesevariablesintothreepotentiallyoverlap-
ping categories: personal, sociocultural, and economic [10].
Personal factors are patient characteristics not amenable to
intervention(i.e.,ageormedicalhistory),whilesociocultural
variables include breast cancer awareness and stigma of
disease, and economic variables include occupation and cost
of care. To effectively prevent delayed patient presentation in
LIDCs, the specific causative variables contributing to delay
mustbeidentifiedoutofthemyriadofpotentialcontributory
ones (Table 1).
O n eL I D Cw i t hap a u c i t yo fr e s e a r c hi sH a i t i ,w h i c hm a y
be “faced with the worst health and human development
statistics in the region” [11]. Currently, Haiti is estimated
to exhibit a breast cancer incidence of 4.4 per 100,000
females per year and mortality of 2.0 per 100,000 females
per year for an approximate relative mortality of 45% [12]. In
comparison, the United States has a higher incidence of 121.2
per 100,000 females per year and a higher mortality of 23.5
per 100,000 females per year, but a much lower approximate
relative mortality of 19% [13]. Unfortunately, Haiti’s current
epidemiological estimates are modeled from data of similar
and surrounding nations. To address the concerning lack of
in-country data, the Program in Global Surgery and Social
Change (PGSSC) at Harvard Medical School, in conjunc-
tion with Partners In Health and Zanmi Lasante (PIH/ZL),
launched the Haiti Breast Cancer Initiative (HBCI): the first
prospective hospital-based Haitian breast cancer registry.
Th e r e f o r e ,th ep u rpo seo fth i ss t u d yi st ou sei n i ti a lH BC I
results to (1) identify the personal, sociocultural, and eco-
nomic barriers-to-care that delay breast cancer presentation
within this Haitian patient population and (2) recommend
personalizedinterventionsthatpreemptpatientdelay,reduce
stageatpresentation,andconsequentlyimprovemortality,in
anefforttocontroltheburdenofbreastcancerdiseasewithin
Haiti.
2. Materials and Methods
2.1. Study Population and Design. The HBCI is a prospective,
hospital-based breast cancer registry at the Breast Clinic of
the Partners In Health (PIH)/Zanmi Lasante (ZL) Hˆ opital
Bon Sauveur in Cange, Haiti. Any female patient over 18
years old who presents for care is offered the chance to be
enrolled;informedconsentisobtainedfromanywillingpart-
icipant. The weekly Breast Clinic, run by one of the senior
authors (Ruth Damuse), offers screening, diagnosis, and
socialworkservices.Patientsareprovidedwithmedicaltreat-
mentssuchaschemotherapyandmaybereferredforsurgical
interventionrangingfrombiopsytomodifiedradicalmastec-
tomy. All care is provided free of charge.
Thedatabasecollectsstandardizeddataonpatientdemo-
graphics, barriers-to-care, medical history, clinical presenta-
tion, diagnostic workup including imaging and pathology,
surgical and medical treatments, and outcomes including
complications and disease status at points of followup.
Regarding barriers-to-care and presentation delay, patients
wereasked“ didanyofthefollowingpreventyoufromcoming
to clinic sooner?” and provided a list of 14 yes/no answers
(Table 3).IRBapprovalwasobtainedbybothChildren’sHos-
pital Boston and PIH/ZL.
2.2. Statistical Analysis. Delayed presentation was defined as
12 weeks or greater from discovery of first breast cancer sign
or symptom to initial presentation to a Haitian healthcare
provider, in agreement with the existing literature [14]a n d
b a s e do ns y s t e m a t i c a l l yr e v i e w e de v i d e n c et h a td u r a t i o n s
longer than this correlate with decreased survival, though
it is likely that delay is a continuous variable in regard to
outcome [9]. Summary statistics were tabulated using 𝜒
2 to
compare proportions and Wilcoxon rank-sum to compare
sample medians. A multivariate logistic regression model
using patient demographics and survey responses to predict
delayedpresentationwasemployed.Tobeincluded,potential
covariates had to exhibit statistical significance (𝑃 < 0.05)
on univariate comparison between patients with and without
delay. The model’s accuracy was measured by the Hosmer-
Lemeshow Goodness-of-Fit test to test calibration and 𝑐-
statistic to test discrimination. Two-sided 𝗼 = 0.05 indicated
significanceinalltests.AllstatisticalanalyseswereperformedJournal of Oncology 3
N = 123 patients accrued
into HBCI from
March 2012 to March 2013
n=9 0patients reported
symptom-presentation interval
n=3 3patients did not
report interval
n=5 2patients did not
delay presentation (<12wks)
n=3 8patients delayed
presentation (≥12wks)
Figure 1: HBCI patient flowchart. Note: patients in red boxes
reportedsymptom-presentationintervalandformedthebasisofour
study.
viacommercially-availableSTATAv11.1(CollegeStation,TX,
USA).
3. Results
From March 1, 2012 to March 1, 2013, 𝑁 = 123 breast cancer
patientswhopresentedtotheBreastClinicinCangeagreedto
enrollintheHBCI.Ofthistotal,90patientsreportedasymp-
tom-presentation interval and therefore formed the basis for
this study. Of these, 𝑛=5 2 (58%) presented to a health-
care provider less than 12 weeks after discovering their ini-
tial breast-cancer-related sign/symptom (median duration: 1
week, IQR: 1–4 weeks), whereas 𝑛=3 8(42%) waited longer
than12weeksandthereforedelayedtheirpatientpresentation
(median duration: 26 weeks, IQR: 17–77 weeks) (Figure 1).
Several important demographic differences were noted
between the two groups. Patients with delay were less likely
to have completed secondary school or higher (16% versus
43%, 𝑃 = 0.02). In addition, patients with delay were slightly
older (median 49 versus 45 years, 𝑃 = 0.04). There were
nostatisticallysignificantdifferencesbetweenthetwogroups
with respect to marital status, employment status, breast
cancer history, time to reach clinic, or method of reaching
clinic (Table 2).
Amongt patients with delay, the three most commonly
cited barriers-to-care were: “I wasn’t bothered by the mass at
first” (18/38, 47%), “I did not know I needed to see a doctor
a n dt h o u g h ti tw o u l dg oa w a y ”( 1 3 / 3 8 ,3 4 % ) ,a n d“ It h o u g h t
treatment might be too expensive” (8/38, 21%). Furthermore,
when comparing survey responses between the two groups,
patients with delay were significantly more likely to claim the
followingasbarriers-to-care:“Iwasafraidofbeingexamined
by a doctor or other health official” (8% versus 0%, 𝑃=
0.04), “I was not bothered by the mass at first” (47% versus
10%, 𝑃 < 0.01), “I was afraid of possibly dying if my breast
was removed” (11% versus 0%, 𝑃 = 0.02), and “I thought
treatment might be too expensive” (21% versus 6%, 𝑃 = 0.03)
(Table 3).
Finally, a multivariate logistic regression model was con-
structed using the following covariates as they exhibited sta-
tisticalsignificanceonunivariatecomparison:age,loweredu-
cation status (defined as receiving no education or attending
Ignorance of hospital location
Belief that the mass would
spontaneously resolve
Odds ratio [95% CI]
Employment status
Method of reaching clinic
Time to reach clinic
Marital status
Older age
Lower education status
Failure to initially recognize
mass as significant
Fear of cost of treatment
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Figure 2: Logistic regression analysis. Note: univariate logistic
regression for covariates not meeting the inclusion criteria into
the multivariate model is shown for reference. Only covariates that
exhibit significance in the multivariate analysis are considered as
independent risk factors for delayed patient presentation (barriers-
to-care). Multivariate logistic regression model: 𝑐 statistic = 0.807,
concordant pair percentage = 80.7%, discordant pair percentage =
19.3%,Hosmer-LemeshowGoodness-of-Fittest:𝜒
2 = 3.95,𝑃 = 0.86
(df = 8).
primary school only), fear of examination (“I was afraid of
being examined by a doctor or other health official”), failure
to initially recognize mass as important (“I was not bothered
by the mass at first”), fear of treatment (“I was afraid of
po s s i b l yd y i n gi fm yb r ea s tw a sr e m o v ed ” ) ,a n df ea ro fc o s to f
treatment(“Ithoughttreatmentmightbetooexpensive”).Of
these, three variables were shown to independently increase
the odds of delaying presentation: lower education status
(OR = 5.6, 𝑃 = 0.03), failure to initially recognize mass
as important (OR = 13.0, 𝑃 < 0.01), and fear of cost of
treatment(OR= 8.3,𝑃 = 0.03). Moreover, the model showed
an excellent abilityto predictpatientdelay (𝑐 statistic = 0.807,
c o n c o r d a n tp e r c e n t a g e=8 0 . 7 % )a n dfi tt h eo b s e r v e dd a t a
well (Hosmer-Lemeshow Goodness-of-Fit test: 𝜒
2 = 3.95,
𝑃 = 0.86)( Figure 2).
4. Discussion
Delayed patient presentation refers to a prolonged interval
(≥12weeks)betweendiscoveryofinitialbreast-cancer-related
s i g n / s y m p t o ma n dp r e s e n t a t i o nt ot h efi r s tq u a l i fi e dm e d i c a l
provideravailable.Patientdelayhasbeenshowntobeamajor
contributor toward advanced stage at presentation and rela-
tively increased mortality in both developing countries and
underserved populations in developed nations [2, 9, 15]. To
our knowledge, this study is the first evaluation of potential
personal,sociocultural,andeconomicriskfactorsfordelayed
patient presentation (or barriers-to-care) within Haiti.
Our findings suggest that patient delay is a preva-
lent, complex, and multifactorial phenomenon that spans
sociocultural and economic domains. Notably, we observed
a profound difference in symptom-presentation duration4 Journal of Oncology
Table 2: Patient characteristics.
Presentation not delayed
𝑁 = 52 (58%)
Presentation delayed
𝑁 =3 8( 4 2 % )
𝑃-value
Age (yrs)
1 45 (39–53) 49 (43–62) 0.04
Symptom-presentation duration(wks)
1 1 (1–4) 26 (17–77) <0.01
Marital status
Single, divorced, widowed 18 (35%) 17 (45%) 0.48
Married 21 (40%) 15 (39%)
Not reported 13 (25%) 6 (16%)
Education status
None 5 (10%) 11 (29%)
Primary school 19 (37%) 13 (34%) 0.02
Secondary school 16 (31%) 6 (16%)
University 6 (12%) 0 (0%)
Not reported 6 (12%) 8 (21%)
Employment status
Unemployed 30 (58%) 28 (74%) 0.29
Employed 20 (38%) 9 (24%)
Not reported 2 (4%) 1 (3%)
Prior history of breast cancer
None 47 (90%) 36 (95%) 0.22
Yes 01 ( 3 % )
Not reported 5 (10%) 1 (3%)
Time to reach clinic (hrs)
1 3( 3 - 4 ) 3( 3 - 4 ) 0.71
Method of reaching clinic
Walk 0 (0%) 1 (3%)
Car 3 (7%) 3 (8%) 0.53
Public transportation 40 (89%) 32 (86%)
Not reported 2 (4%) 1 (3%)
1Median (interquartile range).
Table 3: Barriers-to-care survey: did any of the following prevent you from coming to clinic sooner?
Survey response Patients without delay
(𝑁 =5 2 )
Patients with delay
(𝑁 =3 8 )
𝑃-value
I was afraid of being examined by a doctor or other health official 0( 0 % ) 3( 8 % ) 0.04
I had or knew someone who had a bad experience at a hospital before 0 (0%) 0 (0%) n/a
I was not bothered by the mass at first 5 (10%) 18 (47%) <0.01
I did not know I needed to see a doctor and thought it would go away 10 (20%) 13 (34%) 0.11
I did not know where an appropriate medical facility was 1( 2 % ) 2( 5 % ) 0.38
Iw a st o ob u s ya tm yh o m eo rj o b 0 (0%) 1 (3%) 0.24
I was afraid of treatments, including potentially losing my breast 0 (0%) 2 (5%) 0.10
Id i dn o tw a n ta n y o n ek n o w i n gt h a tIh a dam a s s 0 (0%) 1 (3%) 0.24
I tried another treatment or visited another healer first 0 (0%) 1 (3%) 0.24
I was afraid of possibly dying if my breast was removed 0 (0%) 4 (11%) 0.02
I was afraid it might be cancer 0 (0%) 2 (5%) 0.10
I thought treatment might be too expensive 3 (6%) 8 (21%) 0.03
It was too expensive to travel to the clinic 0 (0%) 0 (0%) n/a
The clinic was too far away for me to travel to 0 (0%) 0 (0%) n/aJournal of Oncology 5
between patients without delay (median: 1 week, IQR 1–4
weeks) and patients with delay (median: 26 weeks, IQR: 17–
77 weeks). This bimodal distribution suggests the existence
of two separate groups within our patient population. When
comparing these groups on univariate analysis, the following
were significantly associated with delay: lower education
status, fear of examination, failure to initially recognize mass
as important, fear of treatment, fear of cost of treatment, and
(to a lesser extent) older age (Table 2).
Of these potential barriers-to-care, only three survived
the most rigorous multivariate logistic regression analysis.
Specifically, lower education status (defined as receiving no
formaleducationorattendingprimaryschoolonly)increased
t h eo d d so fd e l a ya l m o s ts i x f o l d ,w h i l ef e a ro fc o s to ft r e a t -
ment increased the odds more than eightfold, and failure to
initiallyrecognizemassasimportantincreasedtheoddsthir-
teenfold. Hence, out of the myriad of potential contributory
factors, these three constitute the most meaningful barriers-
to-care in this setting (Figure 2).
Similar research conducted in other LIDCs has yielded
varying results. One study in South India found that being
unmarried and lower education level were associated with
delayed presentation [16]. Another study of Iranian women
observedanassociationwithpositivefamilyhistoryofbreast
cancer [17]. A case series in Ghana listed privious medical
consultation, ignorance about breast cancer, and fear of
mastectomy as the three most cited factors leading to delay
[18]. These heterogeneous results may stem from variations
in study methodology and/or differences between LIDCs
themselves, where cultures and economies can vary tremen-
dously. A recent systematic review by our group observed
strong evidence for personal and economic factors related to
patient delay and moderate evidence for sociocultural ones
in LIDCs, but noted that, while the current evidence for such
sociocultural factors remains moderate, this may reflect the
current paucity of (high-quality) studies, and future research
is required to ascertain the true relationship between socio-
cultural variables and patient delay in the developing world
[10].
Our study suffers from several limitations. First, the
HBCI is a hospital-based registry that recruits patients who
present for treatment in the PIH/ZL system. As such, the
likelihood of missing patients who present to other facilities
or do not present at all remains high. These missed patients
may have different rationalesfor not presenting for care, pro-
ducingpotentialselectionbias.Forinstance,itisconceptually
feasible that HBCI patients are less dissuaded by costs of
travel and treatment than patients who did not present at all.
Thus, our study may understate the importance of economic
barriers-to-care. However, a comprehensive population-
b a s e dr e g i s t ryi sc u r r e n t l yn o tf e a s i b l eg i v e nH a i t i ’ sp r o f o u n d
resource constraints. Second, patient delay was assessed ret-
rospectivelyatthepointofpresentation,introducingpossible
measurementbias.Patientsmayhavemisestimatedthedura-
tion of delay, or may potentially have presented to other sites
first.However,thisbiasislesslikelytoaffectourresults,given
the extreme difference in symptom-presentation duration
between the two patient groups (median 1 week versus 26
weeks, 𝑃 < 0.01) and the large catchment area and free
natureofcareattheHˆ opitalBonSauveur[19].Furthermore,a
prospectiveassessmentofdelaywouldbeunethicalandinfea-
sible, so this bias is inherently unavoidable. Third, although
the possibility of unknown confounding remains, this study
utilized high-powered multivariate logistic regression con-
trolling for demographics and other potential barriers-to-
care, so this potential is minimized as best possible.
Th efi n d i n g so ft h i ss t u d yc a nb eu s e dt oo p t i m i z ef u t u r e
interventions aimed at preempting patient delay in Haiti.
First, from an advocacy standpoint, the Haitian Ministry of
HealthandPIH/ZLcouldembarkonaneducationalandpub-
lic relations campaign that educates women on how to better
recognizetheinitialsignsandsymptomsofbreastcancerand
emphasizestheneedforpresentationtoahealthcareprovider
for any suspicious findings. It is important to emphasize to
women that a mass or lump that is not initially bothersome
may nonetheless portend cancer and thereby require proper
evaluation.Inparticular,intheseniorauthors’(RuthDamuse
and Ainhoa Costas) experience, lack of pain tends to be the
most common reason for patients not to present for eval-
uation, though future surveys are required to confirm this.
Second, the real and perceived economic barriers to breast
cancercaremustbeaddressed.Boththeactualandperceived
costs of treatment must be reduced, either by reducing the
cost itself or by advertising that treatment at certain sites is
already free (PIH/ZL offers free treatment at Cange). Poten-
tial interventions here could include mass media campaigns
to educate Haitians on breast cancer and train community
health workers to teach breast self-exam (BSE). Though BSE
has not been shown to improve survival as an asymptomatic
screeningtool[20],currentscreeningalternativesinHaitiare
e x t r e m e l yl i m i t e d ,a n dB S Ee d u c a t i o nm a yt e a c ht h i sp a t i e n t
populationtobetterrecognizetheinitialsignsandsymptoms
of breast cancer and present earlier in the natural history of
t h e i rd i s e a s e ;t h i si s s u er e q u i r e sf u r t h e rp r o s p e c t i v es t u d y .
PIH/ZL is currently training its community health workers
to teach cancer understanding and broadcast information
a b o u tb r e a s tc a n c e rp r e v e n t i o na n dt r e a t m e n tv i al o c a lr a d i o
stations. Future research must analyze the effectiveness of
these interventions on enhancing breast cancer awareness
andincluderigorouscost-effectivenessanalysistoaccountfor
resource constraints.
5. Conclusion
Toourknowledge, thisconstitutesthefirst prospectivebreast
cancer study in Haiti. Since patients in LIDCs such as Haiti
present with such advanced disease, controlling the burden
of breast cancer globally will require not solely extending
accesstomoderntherapies,butalsodevelopinginterventions
that help patients present sooner in the natural course of
theirdisease.Tohelpachievethisgoal,ourresearchidentifies
targets for the most pertinent personal, sociocultural, and
economic barriers-to-care. Only by educating women on
the signs/symptoms of breast cancer and the importance
of prompt treatment and by decreasing the perceived and
actual cost of treatment will it be possible to reverse
the alarming increase and human toll of breast cancer in
Haiti.6 Journal of Oncology
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